Financials data is unavailable for this security.
View more
Year on year SAGE Therapeutics Inc grew revenues 1,024.84% from 7.69m to 86.46m while net income improved from a loss of 532.78m to a smaller loss of 541.49m.
Gross margin | 91.75% |
---|---|
Net profit margin | -317.29% |
Operating margin | -349.86% |
Return on assets | -42.95% |
---|---|
Return on equity | -49.34% |
Return on investment | -48.97% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at SAGE Therapeutics Inc fell by 91.65m. However, Cash Flow from Investing totalled 442.91m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 540.59m for operations while cash generated from financing totalled 6.03m.
Cash flow per share | -5.56 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.02 |
---|---|
Tangible book value per share | 9.02 |
More ▼
Balance sheet in USDView more
Current ratio | 10.02 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼